Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Zoetis' Equitape praziquantel-only wormer for horses will be discontinued from the firm's equine product range in October 2018.
Animal Pharm is looking for new authors for its animal health industry reports team.
Boehringer Ingelheim Vetmedica has gained a supplemental US approval for Cystorelin (gonadorelin), which is used in reproductive synchrony programs for cattle.
Patrick Meeus has become Elanco's new senior director of global companion animal product development.
US pet therapeutics company Kindred Biosciences has become a commercial entity around six years after it was founded.
UK firm Animalcare has pencilled a fourth-quarter launch date for its recently-approved Cortacare canine dermatology product.
Last year, TyraTech did the opposite of many companies and offloaded its human health business. Now with a focus on animal health, the Morrisville, North Carolina-based firm can pursue a more disciplined growth strategy. Animal Pharm editor Joseph Harvey spoke to the company's chief executive Bruno Jactel.
Boehringer Ingelheim Animal Health has secured Japanese approval for Zactran (gamithromycin) as an antibiotic treatment of swine respiratory disease.
Australian firm CannPal Therapeutics has signed a research agreement with Eurofins Animal Health to develop a cannabis-derived pain therapeutic for cats.
US firm Zinpro has launched new nutritional dermatology products for dogs and livestock.
Bayer Animal Health has teamed up with Japanese firm Mitsui Chemicals Agro (MCAG) in its search for novel parasite prevention.
Canadian firm Avivagen has gained authorization from the Veterinary Drugs Directorate of Health Canada to use its OxC-beta technology in pet supplements.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.